Selnoflast

• CAT Number: I036202
• CAS Number: 2260969-36-4
• Molecular Formula: C20H29N3O3S
• Molecular Weight: 391.53
• Purity: ≥95%
• Synonyms: 1-(1-ethylpiperidin-4-yl)sulfonyl-3-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)urea
• InChI: InChI=1S/C20H29N3O3S/c1-2-23-11-9-16(10-12-23)27(25,26)22-20(24)21-19-17-7-3-5-14(17)13-15-6-4-8-18(15)19/h13,16H,2-12H2,1H3,(H2,21,22,24)
• InChIKey: OHIFQOUPTWBQLE-UHFFFAOYSA-N
• SMILES: CCN1CCC(CC1)S(=O)(=O)NC(=O)NC2=C3CCCC3=CC4=C2CCC4

Selnoflast (Cat No.: I036202) is a selective and reversible inhibitor of cytosolic phospholipase A2 (cPLA2), an enzyme involved in the release of arachidonic acid and subsequent production of pro-inflammatory eicosanoids such as prostaglandins and leukotrienes. By blocking cPLA2 activity, selnoflast reduces inflammation at the upstream level of the arachidonic acid cascade. It is being explored for therapeutic potential in inflammatory and autoimmune diseases, including rheumatoid arthritis and asthma. Selnoflast offers a targeted approach to modulating inflammatory responses with potentially fewer side effects.

Reference

[1]. Vande Walle L, et al. Drugging the NLRP3 inflammasome: from signalling mechanisms to therapeutic targets. Nat Rev Drug Discov. 2023 Nov 29.
[Content Brief]

[2]. Klughammer B, et al. A randomized, double-blind phase 1b study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of the NLRP3 inhibitor selnoflast in patients with moderate to severe active ulcerative colitis. Clin Transl Med. 2023 Nov;13(11):e1471.
[Content Brief]